Trial reportJMIR mental health2025
Cost-Effectiveness of Internet-Delivered Emotion Regulation Therapy for Adolescents With Nonsuicidal Self-Injury: Within-Trial Analysis of a Randomized Controlled Trial.
Trial report in JMIR mental health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Economic evaluations of preventive interventions for self-harm and suicide: a systematic review.Psychological medicine · 2026Pooled it
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Nonsuicidal self-injury (NSSI) is common among adolescents and is associated with adverse clinical outcomes, as well as suicidal behavior. Current treatments are resource-intensive and may not be accessible to all adolescents with NSSI. Internet-delivered emotion regulation individual therapy for adolescents (IERITA) with NSSI disorder is a promising treatment option, but its cost-effectiveness is unknown. Objective: This study aims to evaluate the cost-effectiveness of IERITA for adolescents with NSSI disorder. Methods: Within-trial cost-effectiveness analysis of a randomized controlled trial at three child and adolescent mental health services in Sweden (n=166). A total of 12 weeks of IERITA plus treatment as usual (TAU) versus TAU only were compared. The primary outcome was the frequency of NSSI at 1-month posttreatment. Secondary outcomes were NSSI remission and quality-adjusted life years (QALYs). Results: IERITA led to reductions in NSSI frequency, a higher proportion of participants with NSSI remission, and more QALYs at 1-month posttreatment, at additional health care costs of US $3663 (95% CI US $2182-$5002) and societal costs of US $4458 (95% CI US $-577 to $9509). The incremental cost of one additional NSSI remission at 1-month posttreatment was US $18,677, and the incremental cost per QALY gained was US $792,244 for IERITA+TAU relative to TAU. IERITA had an 8% probability of being cost-effective at a societal willingness-to-pay threshold of US $84,000 for one QALY at 1-month posttreatment, which increased to 18% at 3-months posttreatment. Conclusions: IERITA delivered adjunctive to TAU led to improvements in NSSI frequency, remission, and QALYs, at additional costs compared to TAU only. This study provides an estimate of the additional cost of delivering IERITA; however, future studies should include longer follow-up periods to better assess the magnitude of the effects on QALYs and societal costs.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.